The European Commission has approved the anti-VEGF therapy Lucentis (ranibizumab) to treat patients with visual impairments such as macular edema secondary and retinal vein. Read more on Reuters.
The European Commission has approved the anti-VEGF therapy Lucentis (ranibizumab) to treat patients with visual impairments such as macular edema secondary and retinal vein. Read more on Reuters.
No comments:
Post a Comment